Summary: SG293 represents a differentiated approach for enabling potent and precise in vivo CAR T therapy for both oncology and autoimmune indications, potentially avoiding key off-target concerns.

In patients with longer-standing disease (3-15 years since diagnosis), C-peptide levels were generally preserved through Week 52 (12-week treatment period + 40-week follow-up), with only a modest ...